FeesSafety
Pluang+

Icahn Enterprises reports $225M Q3 loss but sees $1.7B gain in CVI value; declares $0.50 quarterly distribution.

03 Nov 2026, 13:33 WIB
PRNewsWire
View Source
Bearish
Icahn Enterprises reports $225M Q3 loss but sees $1.7B gain in CVI value; declares $0.50 quarterly distribution.

Icahn Enterprises reported a net loss of $225 million for Q3 2026, impacted by $522 million losses on refining hedges but offset by a $1.7 billion increase in the value of its majority-owned subsidiary CVI. The company declared its 86th consecutive quarterly distribution of $0.50 per depositary unit. Additionally, CVR Energy, a subsidiary, announced a $4.2 billion acquisition of two refineries and a marketing platform from Marathon Petroleum, expected to significantly boost EBITDA and earnings per share. Despite short-term losses, the indicative net asset value rose by $865 million since June 2026, reflecting strong underlying asset growth.

Icahn Enterprises L.P.'s Q3 2026 results include a net loss of $225 million despite a $1.7 billion rise in subsidiary value. For readers following the Energy sector, here is Pluang's market snapshot as of Nov 03, 2026 17:51 WIB: out of 79 priced US Energy stocks, 70 rose and 6 fell. Marathon Petroleum Corp (MPC) traded at USD 440.00 with a 1-day change of +2.23% and Pluang order activity showing 87% Sell / 13% Buy, Nextpower Inc. (NXT) at USD 93.10 with +2.16% change and balanced order activity, and Kosmos Energy Ltd. (KOS) at USD 2.52 with +2.02% change and a slight buy bias.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
2 hours ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
2 hours ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
2 hours ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
3 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App